Macroprolactinemia: the consequences of a laboratory pitfall.
The objective of this study was to assess the prevalence of macroprolactin, a macromolecule with reduced bioactivity, in hyperprolactinemic patients. Prolactin was measured before and after precipitation of macroprolactin by polyethylene glycol in 306 patients. Only patients with prolactin values >700 mIU/L (n = 270) entered the study. In 23% of the patients, macroprolactinemia was found. In women, the occurrence of macroprolactinemia increased with advancing age (< 30 yr: 16%; 30-45 yr: 28%; > 45 yr: 42%; p < 0.05). A priori clinical signs of hyperprolactinemia (morphological abnormalities in pituitary imaging, galactorrhea infertility) occurred significantly less frequently in macroprolactinemia than in true hyperprolactinemia. In eight females macroprolactinemia and true hyperprolactinemia appeared simultaneously. To avoid diagnostic and therapeutic pitfalls, the screening for macroprolactinemia of all patients with prolactin levels of > 700 mIU/ L is recommended.
Toldy
Erzsébet
E
Central Laboratory, Markusovszky Teaching Hospital of County Vas, Szombathely, Hungary.
Löcsei
Zoltán
Z
Szabolcs
István
I
Góth
Miklós I
MI
Kneffel
Pál
P
Szöke
Dominika
D
Kovács
Gábor L
GL
D000328:Adult; D002648:Child; D005260:Female; D005590:Fractional Precipitation; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000175:diagnosis; D008163:Luminescent Measurements; D008297:Male; D011092:Polyethylene Glycols / Q000737:chemistry; D011388:Prolactin / Q000097:blood*; D012189:Retrospective Studies
C060678:prolactin, polymeric; D011092:Polyethylene Glycols; D011388:Prolactin